HOME >> BIOLOGY >> NEWS
Report in Science on x-ray crystal structure of matrix Metalloproteinase-2 (MMP-2)

MMP-2 is a key target for anti-cancer drug development

Research Triangle Park, N.C.--June 4, 1999-- BioStratum Incorporated announced today the publication of a paper in the journal SCIENCE (volume 284, pages 1667-1670) reporting the three-dimensional structure of the matrix metalloproteinase-2 (MMP-2), a key molecular target for a number of anti-cancer drug candidates currently in clinical development. This work was completed by one of BioStratum's founding scientists, Dr. Karl Tryggvason of the Karolinska Institute, Stockholm, Sweden.

The elucidated structure of MMP-2 provides valuable information on the function and regulation of this important enzyme, and provides for the design of improved MMP-2 specific inhibitors for clinical evaluation. BioStratum owns intellectual property rights to this technology and to new and improved MMP-2 inhibitors that may be identified.

Matrix metalloproteinases (MMPs) are involved in tissue growth and wound repair. MMPs work by degrading substances in the extracellular matrix (the area outside of cells) thereby enabling the movement and expansion of cells, the deposition of new extracellular matrix, and the subsequent development of new tissue. MMP-2 acts directly on type IV collagen, a principal component of the basal lamina, a specialized form of the extracellular matrix. The activation of MMPs has been implicated in the invasive growth and spread of tumors. Several clinical studies are in progress evaluating the effectiveness of MMP inhibitors as anti-cancer agents, and many more are projected to enter clinical trials in the near future.

The elucidated molecular structure is the culmination of seven years of effort in Dr. Tryggvason?s laboratory. "This advance is providing important insights into the catalytic and regulatory mechanisms of this enzyme. It also provides an additional tool to aid in the design of improved MMP inhibitors to combat the spread of cancer," said Dr. Tryggvason.<
'"/>

Contact: J. Wesley Fox, Ph.D.
info@biostratum.com
919-572-6515
Noonan/Russo Communications
4-Jun-1999


Page: 1 2 3

Related biology news :

1. Report outlines vision and recommendations for microbiology in the 21st Century
2. Report outlines steps needed to lessen smallpox threat
3. Reporters from Science Magazine to receive ASM Public Communications Award
4. Report in BioScience details global decline of nonmarine mollusks
5. National Academies news: Report on EPAs particulate matter research
6. Report details growing climate change threat to coral reefs
7. Report to aid nation in managing freshwaters
8. Report examines use of antibiotics in agriculture
9. Report offers action plan for curbing diseases that kill millions
10. Report focuses on the science and safety of genetically modified crops
11. Report considers role of science in a world made vulnerable by terrorism

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/18/2017)... ROCKVILLE, Md. , Jan. 18, 2017  In ... with respect to mergers and acquisitions (M&A), and Kalorama ... reasons for such acquisitions have been shifting. Generally, uncertainty ... and the U.S. has changed the acquisitions ... situation has resulted in companies buying partners outside of ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... business in Hong Kong. , Nerium International is proud to introduce its Age-Defying ... Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
Cached News: